Henlius CEO Wenjie Zhang Takes Over Chairman Role
Current Chairman Qiyu Chen To Become Non-Executive Director
Executive Summary
Henlius has reshuffled its C-suite, with chairman Qiyu Chen stepping down from the role to take up a position as non-executive director and CEO Wenjie Zhang poised to step into his shoes.
You may also be interested in...
Who’s Hired? Teva Names New BD Chief
Teva has named a new executive vice president in charge of business development for the off-patent industry giant. At the same time, biosimilars specialist Henlius has appointed a fresh CEO, Coherus has added a new director and Olon has recruited a biotech chief.
Henlius Gets Fourth Chinese Biosimilar With Bevacizumab Nod
Shanghai Henlius Biotech has celebrated its fourth Chinese biosimilar approval with the NMPA’s endorsement of its bevacizumab biosimilar. The company is also working on an ophthalmic version to treat wAMD.
Cancer Drug Developers Cry Foul As Costs Soar In China
Sheer volume of studies and fierce competition to recruit and enroll required numbers of patients in trials, even in a populous country like China, can quickly jack up new drug development costs.